Search for: "Matthew Rizzolo" Results 1 - 11 of 11
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Aug 2019, 9:15 am by Daniel Hanson
Matthew Rizzolo and Kathryn Thornton, among others, have addressed the constitutional aspects of the decision. [read post]
11 Aug 2019, 9:15 am by Daniel Hanson
Matthew Rizzolo and Kathryn Thornton, among others, have addressed the constitutional aspects of the decision. [read post]
1 Feb 2019, 4:15 am by Scott McKeown
My co-presenter for this webinar will be Matthew Rizzolo, a partner in Ropes & Gray’s IP litigation practice. [read post]
2 Nov 2017, 5:15 am
 (Speakers: Scott McKeown, Douglas Hallward-Driemeier and Matthew Rizzolo) The formal portion of the webinar will begin at 1:30 (EST) and will last for approximately 50-60 minutes. [read post]
16 Sep 2019, 9:16 pm by Scott McKeown
My co-presenter for this webinar will be Matthew Rizzolo, litigation counsel in Ropes & Gray’s intellectual property litigation practice. [read post]
27 Nov 2017, 5:10 am
 (Speakers: Scott McKeown, Douglas Hallward-Driemeier and Matthew Rizzolo) The formal portion of the webinar will begin at 1:30 (EST) and will last for approximately 50-60 minutes. [read post]
25 Apr 2018, 11:15 am by Scott McKeown
Ropes & Gray speakers will be PTAB practice chair Scott McKeown, Appellate and Supreme Court practice chair Douglas Hallward-Driemeier, and patent litigator Matthew Rizzolo. [read post]
24 Oct 2019, 7:20 pm by Scott McKeown
My co-presenters for this webinar will be Ropes & Gray’s Appellate & Supreme Court Practice Chair Doug Hallward-Driemeier and IP Litigation Partner Matthew Rizzolo. [read post]
30 Apr 2018, 4:43 am by Scott McKeown
On this program I will be joined by Ropes & Gray’s Appellate and Supreme Court practice chair Douglas Hallward-Driemeier, as well as patent litigator Matthew Rizzolo. [read post]
28 Jan 2019, 11:22 pm by Filko Prugo
Filko Prugo, Charlotte Jacobsen, Matthew Rizzolo and Henry HuangFor manufacturers of biologics and biosimilars facing potential patent litigation in the U.S., the Biologics Price Competition and Innovation Act (BPCIA) imposes a complex statutory scheme that restricts the timing and control of disputes in federal district court. [read post]